catalyst · primary record
Fosmanogepix IV infusion + Standard of care antifungal therapy + Fosmanogepix oral tablet
Phase readout · 2028-02-01 · Invasive Mold Infections
| Company | Basilea Pharmaceutica |
|---|---|
| Ticker | Not stated |
| Impact | high |
| Detail | P3 primary completion · NCT06925321 |
| Source | ClinicalTrials.gov |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:44:34.547Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: Basilea Pharmaceutica:Fosmanogepix IV infusion + Standard of care antifungal therapy + Fosmanogepix oral tablet:2028-02-01:P3 primary completion · NCT06925321
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.